Hansoh Pharmaceutical Group Co Limited/ADR
HNPHYN/A
NASDAQBiotechnology🇺🇸North AmericaSHANGHAI
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 2026
Market Overview
Stock performance and key metrics
HNPHY News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
HS-20093
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel
Osteosarcoma
HS-20089
Ovarian Cancer
HS-10380 Low Dose
SCHIZOPHRENIA 1 (Disorder)
HS-20094
Overweight and Obesity
HS-10542
Paroxysmal Nocturnal Hemoglobinuria
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) | - | - |
Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma | - | - |
HS-20089 | Phase 2 | Ovarian Cancer | - | - |
HS-10380 Low Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
HS-20094 | Phase 2 | Overweight and Obesity | - | - |
HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply